[144] Medpace Holdings, Inc. SEC Filing

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) – Form 144 filing discloses a proposed sale of up to 3,000 common shares through Fidelity Brokerage Services on or about 28 Jul 2025. At the filing’s stated aggregate market value of US$1.35 million, the sale equates to roughly US$450 per share and represents only about 0.01 % of the 28,093,026 shares outstanding.

The seller—whose name is not listed—acquired the shares directly from the issuer via three events: (i) vesting of 1,823 restricted shares on 28 Feb 2024, (ii) exercise of 1,000 stock-option shares on 6 May 2022, and (iii) exercise of 177 stock-option shares on 27 Oct 2020. No securities were sold by this person during the past three months, and the standard representation affirms no knowledge of undisclosed adverse information.

Because Form 144 is only a notice of intent, execution is not guaranteed. Given the modest size relative to the public float and absence of additional operational or financial disclosures, the filing is unlikely to be materially impactful for MEDP’s near-term fundamentals but does add a datapoint on insider sentiment.

Positive

• None.

Negative

• Insider proposes to sell 3,000 MEDP shares valued at US$1.35 million, signalling potential profit-taking.
• Filing may be interpreted as insider sentiment slowing, though magnitude is minor.

Insights

Securities Analyst

TL;DR – Minor insider sale notice; immaterial to valuation unless part of larger trend.

The 3,000-share Form 144 equals ~0.01 % of outstanding shares and does not meaningfully alter supply-demand dynamics. The US$1.35 million value is modest relative to MEDP’s ~US$13 billion market cap. No pattern of recent sales is indicated, reducing concerns over sustained insider distribution. I view the disclosure as neutral: it neither improves nor degrades the investment thesis but should be logged for trend monitoring.

Corporate Governance Expert

TL;DR – Routine compliance filing; governance risk remains unchanged.

Form 144 ensures transparency around potential insider transactions. Absence of adverse-information disclaimer breaches is positive. The anonymous filer’s sale proceeds from vested equity compensation, a standard liquidity event. No Rule 10b5-1 plan is referenced, but lack of recent sales mitigates aggregation issues under Rule 144(e). Overall governance impact is negligible, with no red flags detected.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	3000	1350000.00	28093026	07/28/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/28/2024	Restricted Stock Vesting	Issuer			1823	02/28/2024	Compensation
Common	05/06/2022	Stock Option Exercise	Issuer			1000	05/06/2022	Cash
Common	10/27/2020	Stock Option Exercise	Issuer			177	10/27/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Medpace (MEDP) shares are covered by this Form 144?

The notice covers 3,000 common shares.

What is the market value of the proposed MEDP share sale?

The aggregate market value is approximately US$1.35 million.

When is the planned sale date for the MEDP shares?

The filer lists an approximate sale date of 28 July 2025.

What percentage of Medpace’s shares outstanding does this sale represent?

About 0.01 % of the 28,093,026 shares outstanding.

How were the shares originally acquired by the seller?

Via restricted-stock vesting (1,823 shares) and two stock-option exercises (1,000 & 177 shares).

Were any MEDP shares sold by this person in the prior three months?

No. The filing states "Nothing to Report" for past-three-month sales.